Skye Bioscience, Inc. (SKYE)
| Market Cap | 18.25M -84.9% |
| Revenue (ttm) | n/a |
| Net Income | -57.33M |
| EPS | -1.45 |
| Shares Out | 35.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 335,310 |
| Open | 0.4900 |
| Previous Close | 0.4717 |
| Day's Range | 0.4650 - 0.5400 |
| 52-Week Range | 0.2760 - 4.9900 |
| Beta | 2.99 |
| Analysts | Buy |
| Price Target | 7.33 (+1,311.24%) |
| Earnings Date | Aug 7, 2026 |
About SKYE
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in S... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 1,311.24% from the latest price.
News
Skye Bioscience Transcript: AGM 2026
The meeting established a quorum and approved all proposals, including director elections, auditor ratification, an increase in authorized shares, and executive compensation. No questions were raised by stockholders during the Q&A session.
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic h...
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Skye Bioscience (SKYE) to $6 from $13 and keeps an Overweight rating on the shares. The firm notes Skye ended Q1 2026…
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
“Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of…
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience Quarterly report: Q1 2026
Skye Bioscience has published its Q1 2026 quarterly earnings report on May 11, 2026.
Skye Bioscience Earnings release: Q1 2026
Skye Bioscience released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Skye Bioscience Slides: Corporate presentation
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Slides: Corporate presentation
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen...
Skye Bioscience Earnings Call Transcript: Q4 2025
Nimacimab's CBeyond program showed strong additive weight loss and safety in combination with GLP-1s, with higher dose studies and subcutaneous delivery advancing toward Phase IIb. Cash runway extends through Q4 2026, and early APC platform data support future pipeline growth.
Skye Bioscience Earnings release: Q4 2025
Skye Bioscience released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Skye Bioscience Annual report: Q4 2025
Skye Bioscience has published its Q4 2025 annual report on March 10, 2026.
Skye Bioscience Slides: Q4 2025
Skye Bioscience has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 10, 2026.
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
Cash, cash equivalents, and short-term investments totaled $25.7M as of December 31, 2025. “All of the data generated and reported in the past year along with the incremental data highlighted…
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modul...
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Skye Bioscience Slides: Corporate presentation
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on February 21, 2026.
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
Skye Bioscience (SKYE) announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab, its peripherally-restricted ...